| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Technical Briefs |
1 Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, University of Minnesota School of Medicine, Minneapolis, MN 55415
aaddress correspondence to this author at: Clinical Laboratories MC 812, Hennepin County Medical Center, 701 Park Ave., Minneapolis, MN 55415; fax 612-904-4229, e-mail fred.apple@co.hennepin.mn.us
| The first 300 words of the full text of this article appear below. |
Numerous studies have monitored the appearance of both cardiac and skeletal muscle proteins and enzymes after short- and long-term exercise regimens. Both animal and human exercise models have attempted to determine whether the stress of long-duration exercise, such as a marathon race (42.2 km), could cause myocardial necrosis and the release of cardiac-specific proteins, such as cardiac troponin I (cTnI) or T (cTnT) (1)(2)(3)(4). In a rat animal model, the severe stress of swimming for 5 h caused microscopic evidence of myocardial necrosis, which led to substantially increased serum cTnT concentrations (1). However, in a less stressful regimen of 1–3 h of swimming, no evidence of ischemic injury and only very minor alterations in serum cTnT concentrations were detected. Middle-aged male marathon runners had increases in inflammatory and prothrombotic markers within 4 h after completion of a race (5). Increases in cTnI were also observed (6). However, no evidence of microinfarction was found by sestamibi imaging, nor was evidence of left ventricular dysfunction found by B-natriuretic peptide testing (6).
Ischemia-modified albumin (IMA), measured by the albumin cobalt-binding (ACB) test (7), is reported to predict subsequent cTnI results for patients presenting with symptoms of acute coronary syndromes. Furthermore, studies that included percutaneous transluminal coronary angioplasty as a model of transient myocardial ischemia have demonstrated that serum IMA concentrations, as measured by the ACB test, were increased very early after an ischemic event (8); thus, IMA may be a very early indicator of myocardial ischemia before necrosis. To test this hypothesis in healthy persons at very low risk for cardiac disease but at high risk for skeletal muscle damage, we studied the appearance and clearance characteristics of the IMA marker compared with
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  P O Collinson and D C Gaze Ischaemia-modified albumin: clinical utility and pitfalls in measurement J. Clin. Pathol., September 1, 2008; 61(9): 1025 - 1028. [Full Text] [PDF]
|
|
|
|
 |
|
 A Gunduz, A Mentese, S Turedi, S C Karahan, U Mentese, O Eroglu, S Turkmen, I Turan, U Ucar, R Russell, et al. Serum ischaemia-modified albumin increases in critical lower limb ischaemia Emerg. Med. J., June 1, 2008; 25(6): 351 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Giannitsis and H. A. Katus Ability of DNase I activity to detect myocardial ischaemia in vasospastic angina a view through a monocle? Eur. Heart J., December 2, 2007; 28(24): 2955 - 2956. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Prefumo, D. C Gaze, A. T Papageorghiou, P. O Collinson, and B. Thilaganathan First trimester maternal serum ischaemia-modified albumin: a marker of hypoxia-ischaemia-driven early trophoblast development Hum. Reprod., July 1, 2007; 22(7): 2029 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kalay, Y. Cetinkaya, and I. Ozdogru Ischemia-Modified Albumin and Myocardial Ischemia J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2375 - 2375. [Full Text] [PDF]
|
|
|
|
 |
|
 NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF]
|
|
|
|
 |
|
 NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]
|
|
|
|
|
|
E. Sbarouni, P. Georgiadou, G. N. Theodorakis, and D. Th. Kremastinos Ischemia-Modified Albumin in Relation to Exercise Stress Testing J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2482 - 2484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Neilan, J. L. Januzzi, E. Lee-Lewandrowski, T.-T. Ton-Nu, D. M. Yoerger, D. S. Jassal, K. B. Lewandrowski, A. J. Siegel, J. E. Marshall, P. S. Douglas, et al. Myocardial Injury and Ventricular Dysfunction Related to Training Levels Among Nonelite Participants in the Boston Marathon Circulation, November 28, 2006; 114(22): 2325 - 2333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Middleton, R. Shave, K. George, G. Whyte, J. Forster, D. Oxborough, D. Gaze, and P. Collinson Novel application of flow propagation velocity and ischaemia-modified albumin in analysis of postexercise cardiac function in man Exp Physiol, May 1, 2006; 91(3): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Giannitsis and H. A. Katus Mirror, mirror on the wall: the quest for the earliest marker of myocardial ischaemia Eur. Heart J., November 2, 2005; 26(22): 2349 - 2350. [Full Text] [PDF]
|
|
|
|
|
|
P. M. van der Zee, H. J. Verberne, J. P. van Straalen, G. T.B. Sanders, B. L.F. Van Eck-Smit, R. J. de Winter, and J. C. Fischer Ischemia-Modified Albumin Measurements in Symptom-Limited Exercise Myocardial Perfusion Scintigraphy Reflect Serum Albumin Concentrations but Not Myocardial Ischemia Clin. Chem., September 1, 2005; 51(9): 1744 - 1746. [Full Text] [PDF]
|
|
|
|
|
|
F. S. Apple, A. H.B. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R. H. Christenson, M. Mockel, O. Danne, et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome Clin. Chem., May 1, 2005; 51(5): 810 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Borderie, Y. Allanore, C. Meune, J. Y. Devaux, O. G. Ekindjian, and A. Kahan High Ischemia-Modified Albumin Concentration Reflects Oxidative Stress But Not Myocardial Involvement in Systemic Sclerosis Clin. Chem., November 1, 2004; 50(11): 2190 - 2193. [Full Text] [PDF]
|
|
|
|
|
|
D. Roy, J. Quiles, R. Sharma, M. Sinha, P. Avanzas, D. Gaze, and J. C. Kaski Ischemia-Modified Albumin Concentrations in Patients with Peripheral Vascular Disease and Exercise-Induced Skeletal Muscle Ischemia Clin. Chem., September 1, 2004; 50(9): 1656 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Panteghini Role and importance of biochemical markers in clinical cardiology Eur. Heart J., July 2, 2004; 25(14): 1187 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zapico-Muniz, M. Santalo-Bel, J. Merce-Muntanola, J. A. Montiel, A. Martinez-Rubio, and J. Ordonez-Llanos Ischemia-Modified Albumin during Skeletal Muscle Ischemia Clin. Chem., June 1, 2004; 50(6): 1063 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
M K Sinha, D Roy, D C Gaze, P O Collinson, and J-C Kaski Role of "Ischemia Modified Albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes Emerg. Med. J., January 1, 2004; 21(1): 29 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Herrmann, J. Scharhag, M. Miclea, A. Urhausen, W. Herrmann, and W. Kindermann Post-Race Kinetics of Cardiac Troponin T and I and N-Terminal Pro-Brain Natriuretic Peptide in Marathon Runners Clin. Chem., May 1, 2003; 49(5): 831 - 834. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow, J. A. de Lemos, M. S. Sabatine, and E. M. Antman The Search for a Biomarker of Cardiac Ischemia Clin. Chem., April 1, 2003; 49(4): 537 - 539. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
